SBH
BVS icon

Segall Bryant & Hamill’s Bioventus BVS Stock Holding History

Segall Bryant & Hamill’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-281,849
Closed -$1.87M – 579
2025
Q2 		$1.87M Buy
281,849
+232,302
+469% +$1.65M 0.03% 441
2025
Q1 		$453K Sell
49,547
-303,082
-86% -$3.03M 0.01% 554
2024
Q4 		$3.7M Sell
352,629
-25,195
-7% -$298K 0.05% 376
2024
Q3 		$4.51M Buy
+377,824
New +$3.27M 0.06% 348

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JIC
Juniper Investment Company New York $313M AUM 79.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Segall Bryant & Hamill's BVS Position: Q3 2025 in Review

Segall Bryant & Hamill sold out of Bioventus (BVS) in Q3 2025, closing a stake of 281,849 shares — an estimated $1.87M sold.

Segall Bryant & Hamill first reported a position in BVS in Q3 2024 and held it in 4 quarters. The position peaked at $4.51M in Q3 2024. 135 funds tracked by Wall St. Rank hold BVS as of Q3 2025.

  • Segall Bryant & Hamill reported no remaining Bioventus position as of Q3 2025 after selling out during the quarter.
  • Segall Bryant & Hamill sold 281,849 Bioventus shares in Q3 2025, an estimated $1.87M.
  • Segall Bryant & Hamill first reported a position in Bioventus in Q3 2024 and held it in 4 quarters.
  • Segall Bryant & Hamill's Bioventus position peaked at $4.51M in Q3 2024.
  • 135 funds tracked by Wall St. Rank held Bioventus as of Q3 2025.

Based on Segall Bryant & Hamill's 13F filing for Q3 2025, filed 12 Nov 2025.